Abbott Labs Beats Q2 2026 Estimates and Raises Full-Year EPS Outlook

Abbott Laboratories reported second-quarter 2026 adjusted diluted earnings per share (EPS) of $1.31, topping the LSEG consensus of $1.28. Net sales reached $12.593 billion, modestly above the $12.50 billion estimate. On the strength of the results, the company lifted its full-year 2026 adjusted EPS guidance to $5.45–$5.60 from the prior $5.38–$5.58 range. Shares rose roughly 4 % in early trading.

Abbott raises full-year outlook on Q2 earnings beat

The quarter was the first full-year after Abbott’s $21 billion acquisition of Exact Sciences, completed on March 23 2026. The deal, announced in November 2025, added the Cologuard colorectal-cancer screening test and expanded Abbott’s addressable cancer-diagnostics market to over $60 billion. In Q1 2026, the company had trimmed its full-year EPS outlook because of integration costs and near-term headwinds from the acquisition. The Q2 performance shows the acquisition beginning to contribute positively to earnings.

Abbott Laboratories reported stronger-than-expected second-quarter earnings and boosted its full-year profit forecast, citing momentum in medical devices and diagnostics.

• Adjusted EPS (Q2): $1.31 vs. $1.28 consensus (+2.3 %).

Abbott raises full-year outlook on Q2 earnings beat

• Net sales (Q2): $12.593 billion vs. $12.50 billion consensus (+0.7 %).

Abbott raises full-year outlook on Q2 earnings beat

• Comparable sales growth (overall): 4.8 % (reported) and 4.8 % (comparable).

Abbott raises full-year outlook on Q2 earnings beat

• Diagnostics: $1.660 billion (+42.3 % reported, +2.9 % comparable); Exact Sciences contributed $919 million, accounting for ~63 % of the $1.451 billion year-over-year gain. Cologuard grew mid-teens on a comparable basis.

Abbott raises full-year outlook on Q2 earnings beat

• Medical Devices: $5.853 billion (+9.0 % reported, +8.4 % comparable); electrophysiology up low-teens, diabetes-care devices up 9.5 % comparable.

Abbott raises full-year outlook on Q2 earnings beat

• Nutrition: $871 million reported, down 3.1 % (reported) and 3.6 % (comparable).

Abbott tops earnings estimates, raises outlook as second-half sales ramps up

• Net income (GAAP): $928 million, a 48 % decline driven by $658 million in intangible amortization and other acquisition-related charges. Adjusted net income rose 3.5 %.

Abbott raises full-year outlook on Q2 earnings beat

• Dividend: 410th consecutive quarterly dividend of $0.63 per share, marking 54 years of annual increases.

Abbott Laboratories reported stronger-than-expected second-quarter earnings and boosted its full-year profit forecast, citing momentum in medical devices and diagnostics.

The earnings beat underscores Abbott’s ability to translate the Exact Sciences acquisition into revenue growth, particularly in cancer diagnostics. Strong device and diabetes-care sales offset weakness in nutrition and rapid-diagnostic segments, reinforcing the company’s exposure to chronic-condition markets that are less sensitive to elective-procedure cycles. The raised EPS outlook and sustained dividend signal confidence to investors and support Abbott’s status as a Dividend Aristocrat.

Abbott Laboratories reported stronger-than-expected second-quarter earnings and boosted its full-year profit forecast, citing momentum in medical devices and diagnostics.

• CEO Robert B. Ford said the quarter “reflects the momentum we are building.”

Abbott Laboratories reported stronger-than-expected second-quarter earnings and boosted its full-year profit forecast, citing momentum in medical devices and diagnostics.

• Abbott reaffirmed its full-year comparable-sales growth target of 6.5 %–7.5 % and issued a third-quarter adjusted EPS outlook of $1.38–$1.46.

Abbott tops earnings estimates, raises outlook as second-half sales ramps up

• The company highlighted its “exposure to chronic conditions” as a buffer against potential slowdowns in elective procedures.

Abbott raises full-year outlook on Q2 earnings beat

Analysts note that achieving the lower end of the second-half sales target will require “the nutrition and rapid-diagnostic units to stabilize without putting more pressure on devices and oncology.” A slowdown in elective-procedure volumes or continued weakness in nutrition could jeopardize the sales goal.

Abbott tops earnings estimates, raises outlook as second-half sales ramps up

• “Our second-quarter results reflect the momentum we are building.” — Robert B. Ford, Chief Executive Officer, Abbott Laboratories

Abbott tops earnings estimates, raises outlook as second-half sales ramps up

• Reported net-sales figures vary slightly across sources: $12.6 billion (Article-Chunk 1), $12.59 billion (Article-Chunk 3), and $12.593 billion (Article-Chunk 6). All agree the figure exceeds analyst expectations.

Abbott raises full-year outlook on Q2 earnings beat

• No separate second-half sales outlook was provided, leaving the precise path to the required 8.6 %–10.5 % second-half growth unspecified.

Abbott tops earnings estimates, raises outlook as second-half sales ramps up

Abbott will aim to meet its second-half comparable-sales growth range of 8.6 %–10.5 % to achieve the full-year EPS target. The company announced a $0.63 dividend payable August 17 2026 and a third-quarter adjusted EPS range of $1.38–$1.46. Investors will watch device and oncology performance, as well as any resurgence in nutrition sales, to gauge whether the momentum highlighted by the CEO can be sustained.

Abbott raises full-year outlook on Q2 earnings beat